300601 康泰生物
已收盘 03-25 15:00:00
资讯
新帖
简况
3月24日康泰生物现7765.74万元大宗交易
证券之星 · 03-24 17:01
3月24日康泰生物现7765.74万元大宗交易
康泰生物（300601）披露持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告，3月20日股价下跌0.49%
证券之星 · 03-20
康泰生物（300601）披露持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告，3月20日股价下跌0.49%
康泰生物：预计2025年全年海外业务收入达9,883.53万元，同比增长859.40%
证券之星 · 03-20
康泰生物：预计2025年全年海外业务收入达9,883.53万元，同比增长859.40%
康泰生物最新公告：四价流感病毒裂解疫苗获药品注册证书
证券之星 · 03-20
康泰生物最新公告：四价流感病毒裂解疫苗获药品注册证书
3月19日康泰生物发生6笔大宗交易 成交金额1.2亿元
证券之星 · 03-19
3月19日康泰生物发生6笔大宗交易 成交金额1.2亿元
康泰生物（300601）披露持股5%以上股东一致行动人内部股份转让公告，3月17日股价上涨0.35%
证券之星 · 03-17
康泰生物（300601）披露持股5%以上股东一致行动人内部股份转让公告，3月17日股价上涨0.35%
康泰生物公布国际专利申请：“呼吸道合胞病毒融合前F蛋白突变体及其应用”
证券之星 · 03-17
康泰生物公布国际专利申请：“呼吸道合胞病毒融合前F蛋白突变体及其应用”
康泰生物（300601）披露全资子公司为公司提供2亿元担保进展，3月6日股价上涨1.88%
证券之星 · 03-06
康泰生物（300601）披露全资子公司为公司提供2亿元担保进展，3月6日股价上涨1.88%
3月2日康泰生物发布公告，股东减持209.34万股
证券之星 · 03-02
3月2日康泰生物发布公告，股东减持209.34万股
康泰生物（300601）披露关于更换持续督导保荐代表人的公告，2月25日股价上涨1.34%
证券之星 · 02-25
康泰生物（300601）披露关于更换持续督导保荐代表人的公告，2月25日股价上涨1.34%
康泰生物：研讨推进尼帕病毒疫苗与抗体药物的研发进程
中金财经 · 02-13
康泰生物：研讨推进尼帕病毒疫苗与抗体药物的研发进程
康泰生物：终止对外投资设立合资公司事项
证券之星 · 02-13
康泰生物：终止对外投资设立合资公司事项
合作告吹、净利大跌，康泰生物连遇“倒春寒”
新浪证券 · 02-13
合作告吹、净利大跌，康泰生物连遇“倒春寒”
康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产
新京报 · 02-09
康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产
28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业
第一财经 · 02-08
28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业
康泰生物最新公告：持股5%以上股东袁莉萍拟在一致行动人之间内部转让不超过2.00%股份
证券之星 · 02-06
康泰生物最新公告：持股5%以上股东袁莉萍拟在一致行动人之间内部转让不超过2.00%股份
康泰生物最新公告：终止设立合资公司
证券之星 · 02-06
康泰生物最新公告：终止设立合资公司
康泰生物最新公告：全资子公司民海生物荣获江苏省科技进步奖二等奖
证券之星 · 02-06
康泰生物最新公告：全资子公司民海生物荣获江苏省科技进步奖二等奖
康泰生物最新公告：副总裁于冰因个人原因辞职
证券之星 · 02-06
康泰生物最新公告：副总裁于冰因个人原因辞职
康泰生物：预计2025年全年归属净利润盈利4900万元至7300万元
证券之星 · 01-29
康泰生物：预计2025年全年归属净利润盈利4900万元至7300万元
加载更多
公司概况
公司名称：
深圳康泰生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-02-07
主营业务：
深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗。
发行价格：
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":13.6,"timestamp":1774422198000,"preClose":13.66,"halted":0,"volume":8599021,"delay":0,"changeRate":-0.0044,"floatShares":900000000,"shares":1117000000,"eps":-0.0898,"marketStatus":"已收盘","change":-0.06,"latestTime":"03-25 15:00:00","open":13.61,"high":13.75,"low":13.52,"amount":117000000,"amplitude":0.0168,"askPrice":13.6,"askSize":341,"bidPrice":13.59,"bidSize":261,"shortable":0,"etf":0,"ttmEps":-0.0898,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":5,"adr":0,"adjPreClose":13.66,"symbolType":"stock","openAndCloseTimeList":[[1774402200000,1774409400000],[1774414800000,1774422000000]],"highLimit":15.03,"lowLimit":12.29,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116929755,"isCdr":false,"pbRate":1.68,"roa":"--","roe":"0.51%","epsLYR":0.18,"committee":0.389232,"marketValue":15190000000,"turnoverRate":0.0096,"status":1,"floatMarketCap":12245000000},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2621050315","title":"3月24日康泰生物现7765.74万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050315?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:01","pubTimestamp":1774342891,"startTime":"0","endTime":"0","summary":"证券之星消息，3月24日康泰生物发生大宗交易，交易数据如下：近三个月该股共发生25笔大宗交易，合计成交22.8万手，折价成交7笔，溢价成交17笔。该股近期无解禁股上市。截至2026年3月24日收盘，康泰生物(300601)报收于13.66元，上涨3.72%，换手率1.22%，成交量11.02万手，成交额1.48亿元。该股近半年内有股东持股变动，合计净减持209.34万股，股东增减持明细如下表：该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0046","BK0239"],"gpt_icon":0},{"id":"2620732239","title":"康泰生物（300601）披露持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告，3月20日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620732239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620732239?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:34","pubTimestamp":1774017264,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告》。本次转让后，博普私募基金产品持股比例由1.79%降至1.09%，华宝万盈私募基金产品持股比例由0.83%升至1.52%。本次股份转让属于一致行动人之间的内部转让，合计持股比例未发生变化，不涉及向市场减持，不影响公司治理结构和控制权。华宝万盈私募基金产品将放弃所持股份的表决权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"gpt_icon":0},{"id":"2620780272","title":"康泰生物：预计2025年全年海外业务收入达9,883.53万元，同比增长859.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780272","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620780272?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:12","pubTimestamp":1774005128,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物03月20日在投资者关系平台上答复投资者关心的问题。2025 年，公司海外注册工作稳步推进，相关产品相继取得海外 GMP 认证及多国注册批件，进一步完善公司疫苗产品海外市场布局。预计2025年全年海外业务收入达9,883.53万元，同比增长859.40%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000035391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0046","BK0201"],"gpt_icon":0},{"id":"2620782490","title":"康泰生物最新公告：四价流感病毒裂解疫苗获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620782490?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:10","pubTimestamp":1774001439,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司研发的四价流感病毒裂解疫苗获得国家药监局签发的《药品注册证书》。四价流感病毒裂解疫苗适用于3岁及以上人群，可刺激机体产生抗流感病毒的免疫力，用于预防疫苗相关型别的流感病毒引起的流行性感冒。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000033781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","159646","BK0239","300601"],"gpt_icon":0},{"id":"2620436592","title":"3月19日康泰生物发生6笔大宗交易 成交金额1.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620436592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620436592?lang=zh_cn&edition=full","pubTime":"2026-03-19 16:59","pubTimestamp":1773910747,"startTime":"0","endTime":"0","summary":"证券之星消息，3月19日康泰生物发生大宗交易，交易数据如下：近三个月该股共发生14笔大宗交易，合计成交17.48万手，折价成交7笔，溢价成交6笔。该股近期无解禁股上市。截至2026年3月19日收盘，康泰生物(300601)报收于14.17元，下跌0.49%，换手率1.39%，成交量12.52万手，成交额1.77亿元。该股近半年内有股东持股变动，合计净减持209.34万股，股东增减持明细如下表：该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900027023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0201","300601"],"gpt_icon":0},{"id":"2620473425","title":"康泰生物（300601）披露持股5%以上股东一致行动人内部股份转让公告，3月17日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620473425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620473425?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:20","pubTimestamp":1773757233,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告》。公告显示，持股5%以上股东袁莉萍的一致行动人博普私募基金产品于2026年3月16日通过大宗交易方式将其持有的公司9,215,000股转让给另一一致行动人华宝万盈私募基金产品。本次转让属于一致行动人之间的内部股份转让，不涉及向市场减持，合计持股比例未发生变化。袁莉萍及其一致行动人合计持股仍为21.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"gpt_icon":0},{"id":"2620975084","title":"康泰生物公布国际专利申请：“呼吸道合胞病毒融合前F蛋白突变体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2620975084","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620975084?lang=zh_cn&edition=full","pubTime":"2026-03-17 05:52","pubTimestamp":1773697936,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示康泰生物（300601）公布了一项国际专利申请，专利名为“呼吸道合胞病毒融合前F蛋白突变体及其应用”，专利申请号为PCT/CN2025/118795，国际公布日为2026年3月12日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来康泰生物已公布的国际专利申请1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.97亿元，同比增34.85%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700004329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"gpt_icon":0},{"id":"2617635403","title":"康泰生物（300601）披露全资子公司为公司提供2亿元担保进展，3月6日股价上涨1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635403","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635403?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:29","pubTimestamp":1772807356,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，康泰生物报收于14.08元，较前一交易日上涨1.88%，最新总市值为157.26亿元。近日，康泰生物披露《关于全资子公司为公司提供担保的进展公告》。该担保事项系基于公司2025年4月18日董事会审议通过的授信及互保安排，其中全资子公司为公司提供担保总额不超过100,000万元。截至公告日，公司及子公司对外担保本金余额9,075.16万元，占2024年度经审计净资产的0.94%，无逾期担保及其他担保事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"gpt_icon":0},{"id":"2616332098","title":"3月2日康泰生物发布公告，股东减持209.34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332098","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616332098?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:01","pubTimestamp":1772456472,"startTime":"0","endTime":"0","summary":"证券之星消息，3月2日康泰生物发布公告《康泰生物:关于控股股东的一致行动人减持期限届满暨实施情况的公告》，其股东杜兴连于2025年12月8日至2026年2月27日间合计减持209.34万股，占公司目前总股本的0.1874%，变动期间该股股价下跌3.77%，截止2月27日收盘报15.05元。股东增减持详情见下表：根据康泰生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200037279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300601","BK0201"],"gpt_icon":0},{"id":"2614035961","title":"康泰生物（300601）披露关于更换持续督导保荐代表人的公告，2月25日股价上涨1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614035961","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614035961?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:33","pubTimestamp":1772029997,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，康泰生物报收于15.14元，较前一交易日上涨1.34%，最新总市值为169.1亿元。康泰生物于2026年2月25日发布公告称，因中信建投证券原保荐代表人徐兴文先生工作变动，不再担任公司2021年向不特定对象发行可转换公司债券持续督导保荐代表人。为保证持续督导工作顺利进行，中信建投证券委派贾哲先生自2026年2月25日起接替其职务。公司董事会对徐兴文先生在持续督导期间的贡献表示感谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","300601","BK0046"],"gpt_icon":0},{"id":"2611137150","title":"康泰生物：研讨推进尼帕病毒疫苗与抗体药物的研发进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2611137150","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611137150?lang=zh_cn&edition=full","pubTime":"2026-02-13 17:16","pubTimestamp":1770974175,"startTime":"0","endTime":"0","summary":"近日，公司参与了合成免疫学与疫苗智造北京市重点实验室组织召开疫苗与抗体研发进展协调会，研讨推进尼帕病毒疫苗与抗体药物的研发进程。后续视尼帕病毒传播情况，如国家防控迫切需要，公司将全力配合推进候选疫苗和抗体药物的临床研究与各项准备工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260213/32017665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0046","BK0201","159646","300601"],"gpt_icon":0},{"id":"2611813146","title":"康泰生物：终止对外投资设立合资公司事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2611813146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611813146?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:18","pubTimestamp":1770970688,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物02月13日在投资者关系平台上答复投资者关心的问题。本次对外投资设立合资公司事项尚未实际出资，不会对公司现有业务、财务状况和经营状况产生重大影响，不会影响公司未来的发展规划，不存在损害公司及股东利益的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300024193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0201","BK0046"],"gpt_icon":0},{"id":"2611135986","title":"合作告吹、净利大跌，康泰生物连遇“倒春寒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2611135986","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611135986?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:11","pubTimestamp":1770966660,"startTime":"0","endTime":"0","summary":"近日，深圳康泰生物制品股份有限公司发布公告，宣布终止与阿斯利康投资（中国）有限公司共同设立疫苗合资公司的计划。 在疫苗行业整体承压、公司业绩显著下滑的背景下，这一合作的终止，进一步凸显出康泰生物在战略推进、产品结构与行业适应性方面面临的多重挑战。 从与阿斯利康合作告吹，到新冠疫苗研发终止，再到净利润大幅预减，康泰生物在一年多时间里连续遭遇“倒春寒”。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-02-13/doc-inhmscxc8850648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0201","BK0239","300601"],"gpt_icon":0},{"id":"2610636394","title":"康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636394","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610636394?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:53","pubTimestamp":1770630780,"startTime":"0","endTime":"0","summary":"彼时，双方在协议中约定，公司和阿斯利康计划在经开区共同成立合资公司，开展全球创新疫苗在中国地区的开发注册、本地化生产和商业化。康泰生物2024年营利双降，营收为26.52亿元，同比下降23.75%；实现净利润2.02亿元，同比下滑76.59%。2025年康泰生物则增收不增利。康泰生物表示，因四联苗受百白破免疫程序调整、营业成本上升及研发投入增加等因素影响，致使2025年度净利润较上年同期下降。","market":"hk","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl882026291747522902791.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl882026291747522902791.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1770630815168378.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1770630815168378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK4568","BK4007","BK0201","BK0239","LU2462157665.USD","LU1829250122.USD","LU0109394709.USD","LU2417539215.USD","BK4588","LU0889565916.HKD","BK4585","LU2456880835.USD","BK0046","LU2236285917.USD","159646","AZN","LU0320765992.SGD","300601"],"gpt_icon":0},{"id":"2609270915","title":"28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2609270915","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609270915?lang=zh_cn&edition=full","pubTime":"2026-02-08 12:13","pubTimestamp":1770523980,"startTime":"0","endTime":"0","summary":"康泰生物称“市场环境剧烈变化”。 康泰生物与阿斯利康投资（中国）有限公司设立合资疫苗企业的计划最终还是告吹了。 近日，康泰生物发布公告称，经各方审慎评估与友好协商，决定终止《经济发展合作协议》《条款清单》及对外投资设立合资公司事项。合资公司也将成为阿斯利康在中国首个且唯一的疫苗生产基地。 截至目前，合资公司尚未成立，康泰生物也尚未实际出资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-08/doc-inhmapyc9468285.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-08/doc-inhmapyc9468285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK4568","LU0109394709.USD","AZN","LU1829250122.USD","LU2236285917.USD","BK4588","LU0320765992.SGD","BK0201","LU0889565916.HKD","300601","LU2417539215.USD","LU2456880835.USD","LU2462157665.USD","BK0239","BK4585","159646","BK4007"],"gpt_icon":0},{"id":"2609595896","title":"康泰生物最新公告：持股5%以上股东袁莉萍拟在一致行动人之间内部转让不超过2.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595896","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609595896?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:51","pubTimestamp":1770382277,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司持股5%以上股东袁莉萍拟将其持有的博普私募基金产品的部分公司股份不超过22,330,000股（不超过公司总股本比例2.00%），通过大宗交易方式转让给其一致行动人华宝万盈私募基金产品。此次股份转让计划是股东及其一致行动人之间的内部转让，不涉及向市场减持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0201","BK0046"],"gpt_icon":0},{"id":"2609841595","title":"康泰生物最新公告：终止设立合资公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2609841595","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609841595?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:50","pubTimestamp":1770382200,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，此前披露，公司拟与阿斯利康投资（中国）有限公司（以下简称“阿斯利康”）聚焦疫苗建立战略合作伙伴关系，并在北京经济技术开发区（以下简称“经开区”）设立合资公司。由于市场环境剧烈变化，行业面临比较大的下行压力，新增投资疫苗产业风险比较高，经各方审慎评估与友好协商，决定终止《经济发展合作协议》《条款清单》及对外投资设立合资公司事项。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"gpt_icon":0},{"id":"2609593041","title":"康泰生物最新公告：全资子公司民海生物荣获江苏省科技进步奖二等奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2609593041","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609593041?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:39","pubTimestamp":1770381590,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司全资子公司北京民海生物科技有限公司作为重要参与单位完成的“新发病毒性传染病快速确认与精准防控关键技术创新及应用”项目荣获江苏省科学技术进步奖二等奖。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0201","BK0046"],"gpt_icon":0},{"id":"2609567639","title":"康泰生物最新公告：副总裁于冰因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2609567639","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609567639?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:20","pubTimestamp":1770376850,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司副总裁于冰因个人原因申请辞去公司副总裁职务，其原定任期至2028年1月21日。于冰辞职后，仍在公司担任其他职务。截至公告披露日，于冰未持有公司股份，不存在应当履行而未履行的承诺事项。其辞任不会影响公司正常生产经营和运作。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600035348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","300601"],"gpt_icon":0},{"id":"2607088556","title":"康泰生物：预计2025年全年归属净利润盈利4900万元至7300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607088556","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607088556?lang=zh_cn&edition=full","pubTime":"2026-01-29 18:10","pubTimestamp":1769681434,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物发布业绩预告，预计2025年全年归属净利润盈利4900万元至7300万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900031763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774454485466,"stockEarnings":[{"period":"1week","weight":-0.0427},{"period":"1month","weight":-0.0801},{"period":"3month","weight":-0.096},{"period":"6month","weight":-0.182},{"period":"1year","weight":-0.1383},{"period":"ytd","weight":-0.0752}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.0492},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0073},{"period":"1year","weight":0.1517},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63422人(较上一季度增加3.15%)","perCapita":"14196股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111692万元","survey":" 深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}